From: Bennett, Tate [Bennett.Tate@epa.gov]

Sent: 6/17/2019 4:47:18 PM

To: Beck, Nancy [Beck.Nancy@epa.gov]
Subject: Fwd: EPA-FDA Touch Base on PFAS

Begin forwarded message:

From: "Darwin, Veronica" < darwin.veronica@epa.gov>

Date: June 17, 2019 at 12:46:50 PM EDT **To:** "Bennett, Tate" < <u>Bennett.Tate@epa.gov</u>> **Subject:** RE: EPA-FDA Touch Base on PFAS

I'll ask her. Thanks.

From: Bennett, Tate

Sent: Monday, June 17, 2019 12:46 PM

To: Darwin, Veronica < darwin.veronica@epa.gov>

Subject: Re: EPA-FDA Touch Base on PFAS

Does Nancy Beck need to be on this?

On Jun 17, 2019, at 12:43 PM, Darwin, Veronica <darwin.veronica@epa.gov> wrote:

Frank asked to be on the call. I'm in the process of confirming that as requested by ORD, FDA scientists and science management reps working on PFAS issues will be on the call. Will let you know as soon as I hear back.

٧.

From: Bennett, Tate

Sent: Monday, June 17, 2019 12:41 PM
To: Dunlap, David dunlap.david@epa.gov

Cc: Gillespie, Andrew < Gillespie. Andrew@epa.gov >; Darwin, Veronica

<<u>darwin.veronica@epa.gov</u>>; Fitzmorris, Amanda <<u>fitzmorris.amanda@epa.gov</u>>;

Kramer, Jessica L. < <u>kramer.jessical@epa.gov</u>> **Subject:** Re: EPA-FDA Touch Base on PFAS

Just making sure.

On Jun 17, 2019, at 12:38 PM, Dunlap, David < dunlap.david@epa.gov> wrote:

Tate,

That's up to Frank, but I intend to be on the call. PFAS is an ORD priority.

DDD

David D. Dunlap

From: Bennett, Tate

Sent: Monday, June 17, 2019 12:36 PM

To: Gillespie, Andrew < Gillespie. Andrew@epa.gov >

Cc: Darwin, Veronica < darwin.veronica@epa.gov>; Dunlap, David

<<u>dunlap.david@epa.gov</u>>; Fitzmorris, Amanda <fitzmorris.amanda@epa.gov>; Kramer, Jessica L.

<kramer.jessical@epa.gov>

Subject: Re: EPA-FDA Touch Base on PFAS

Does Frank need to be on call or can we let him know he needs to include their pfas experts?

On Jun 17, 2019, at 12:28 PM, Gillespie, Andrew <Gillespie.Andrew@epa.gov> wrote:

> I would frame it as I offered to brief FDA on EPA's PFAS research and expressed interest in hearing about FDA's ongoing research work, and FDA took us up on it.

So a draft agenda might be:

- 1. Welcome and introductions (FDA, as host of the call)
- 2. Overview of ORD's PFAS research (Gillespie)
- 3. Overview of FDA's ongoing PFAS research (FDA)
- 4. Discussion of common interest and opportunities for follow up (all)

Andrew J. R. Gillespie, Ph. D. Associate Director, US EPA/ORD/NERL ORD Executive Lead for PFAS R&D

Office 919 541 3655 Personal Phone / Ex. 6

From: Darwin, Veronica

Sent: Monday, June 17, 2019 10:48 AM

To: Dunlap, David < dunlap.david@epa.gov >; Gillespie, Andrew < Gillespie. Andrew@epa.gov >; Fitzmorris,

Amanda <fitzmorris.amanda@epa.gov>

Cc: Kramer, Jessica L. <kramer.jessical@epa.gov>;

Bennett, Tate <Bennett.Tate@epa.gov> Subject: FW: EPA-FDA Touch Base on PFAS

Good Morning,

It's my understanding that this call was requested by ORD to have a scientist to scientist discussion with FDA. Will ORD draft an agenda?

Thank you! Veronica

From: Bennett, Tate

Sent: Monday, June 17, 2019 8:53 AM

To: Hageman, Natalie < Natalie.Hageman@fda.hhs.gov > Cc: Gillespie, Andrew < Gillespie.Andrew@epa.gov >; Fitzmorris, Amanda < fitzmorris.amanda@epa.gov >; Dunlap, David < dunlap.david@epa.gov >; Darwin, Veronica < darwin.veronica@epa.gov >; Ross, David P

<ross.davidp@epa.gov>; Kramer, Jessica L.

< kramer.jessical@epa.gov>; Yiannas, Frank

< Frank. Yiannas@fda.hhs.gov >; Mayne, Susan

<<u>Susan.Mayne@fda.hhs.gov</u>>; Musser, Steven M

< Steven. Musser@fda.hhs.gov >; South, Paul

<Paul.South@fda.hhs.gov>; Dooren, Jennifer

<Jennifer.Dooren@fda.hhs.gov>; Zimdahl, Nina

<Nina.Zimdahl@fda.hhs.gov>; Goldman, David

<David.Goldman@fda.hhs.gov>; Middleton, Karlyn

< Karlyn. Middleton@fda.hhs.gov >; Stewart-Downer,

Sherry < Subject: Re: EPA-FDA Touch Base on PFAS

Natalie- I might suggest putting an agenda together for this call since there are various offices at EPA working on various exercises with respect to pfas. Would you like EPA to draft an initial agenda to which you can add to, FDA?

On Jun 13, 2019, at 8:42 AM, Hageman, Natalie <Natalie.Hageman@fda.hhs.gov> wrote:

Good morning,

We're planning to hold this call for 9:30-10:30 on Tuesday, June 18th. The invitation will be sent out shortly. Please let me know if you would like me to include a colleague that isn't included on this email.

Thank you,

Best,

Natalie

From: Hageman, Natalie

Sent: Thursday, June 6, 2019 1:40 PM

To: Gillespie, Andrew

<Gillespie.Andrew@epa.gov>;

Fitzmorris, Amanda

<fitzmorris.amanda@epa.gov>; Dunlap,

David <<u>dunlap.david@epa.gov</u>>;

Darwin, Veronica

<darwin.veronica@epa.gov>; Bennett, Tate < Bennett. Tate@epa.gov >; Ross, David P < ross.davidp@epa.gov > Cc: Kramer, Jessica L. <kramer.jessical@epa.gov>; Yiannas, Frank < Frank. Yiannas@fda.hhs.gov >; Mayne, Susan <<u>Susan.Mayne@fda.hhs.gov</u>>; Musser, Steven M <Steven.Musser@fda.hhs.gov>; South, Paul <Paul.South@fda.hhs.gov>; Dooren, Jennifer <Jennifer.Dooren@fda.hhs.gov>; Zimdahl, Nina <Nina.Zimdahl@fda.hhs.gov>; Goldman, David <David.Goldman@fda.hhs.gov>; Hageman, Natalie <Natalie.Hageman@fda.hhs.gov> Subject: RE: EPA-FDA Touch Base on **PFAS**

Good afternoon, Dr. Gillespie,

I'll be happy to work with your office to set up a meeting after things have settled down a bit. Please let me know if you have an assistant that I should contact regarding your schedule.

Best,

Natalie

Natalie J. Hageman

Executive Assistant to the Center Director

Center for Food Safety and Applied
Nutrition
Office of the Center Director
U.S. Food and Drug Administration
Office: 240-402-2434 | Personal Phone / Ex. 6 |
natalie.hageman@fda.hhs.gov

<image001.png>

<image002.jpg> <image003.jpg> <image004.j
pg> <image005.jpg> <image006.jpg>

From: Yiannas, Frank

Sent: Thursday, June 6, 2019 12:28 PM

To: Gillespie, Andrew

<Gillespie.Andrew@epa.gov>;

Fitzmorris, Amanda

<fitzmorris.amanda@epa.gov>; Dunlap,

David <<u>dunlap.david@epa.gov</u>>;

Darwin, Veronica

<<u>darwin.veronica@epa.gov</u>>; Bennett,

Tate < Bennett. Tate@epa.gov >; Ross,

David P < ross.davidp@epa.gov >;

Mayne, Susan

<<u>Susan.Mayne@fda.hhs.gov</u>>; Musser,

Steven M

<<u>Steven.Musser@fda.hhs.gov</u>>; South,

Paul < Paul. South@fda.hhs.gov >;

Dooren, Jennifer

<Jennifer.Dooren@fda.hhs.gov>;

Zimdahl, Nina

<Nina.Zimdahl@fda.hhs.gov>;

Hageman, Natalie

<Natalie.Hageman@fda.hhs.gov>;

Goldman, David

<David.Goldman@fda.hhs.gov>

Cc: Kramer, Jessica L.

<kramer.jessical@epa.gov>

Subject: RE: EPA-FDA Touch Base on

PFAS

Thanks Andrew. On behalf of FDA, I can say we would welcome this opportunity.

Someone from FDA will get back to you to help us lock-down a date that works for all. If at all possible, I'd like to join.

Thanks

Frank Yiannas

Deputy Commissioner, Food Policy &
Response

U.S. Food and Drug Administration Office of Food Policy & Response

10903 New Hampshire Ave. Silver Spring, Maryland 20993

Tel: 301-796-4500

frank.yiannas@fda.hhs.gov

<image007.png>

From: Gillespie, Andrew <Gillespie.Andrew@epa.gov>

Sent: Thursday, June 6, 2019 7:41 AM

To: Yiannas, Frank

<Frank.Yiannas@fda.hhs.gov

;
Fitzmorris, Amanda

<fitzmorris.amanda@epa.gov

; Dunlap,
David <dunlap.david@epa.gov

; Darwin, Veronica

darwin.veronica@epa.gov; Bennett, Tate Bennett, Tate@epa.gov; Ross,

David P < ross.davidp@epa.gov >;

Mayne, Susan

<<u>Susan.Mayne@fda.hhs.gov</u>>; Musser, Steven M

<<u>Steven.Musser@fda.hhs.gov</u>>; South, Paul <<u>Paul.South@fda.hhs.gov</u>>; Dooren, Jennifer

<Jennifer.Dooren@fda.hhs.gov>;

Zimdahl, Nina

< Nina. Zimdahl@fda.hhs.gov>

Cc: Kramer, Jessica L. kramer.jessical@epa.gov

Subject: RE: EPA-FDA Touch Base on

PFAS

FDA colleagues – thank you for your time yesterday, it was a very interesting discussion. A couple of follow ups...

1. When the heat dies down and we have some time, I would be very interested in a call or meeting with FDA scientists and science management working on PFAS issues, to exchange information about our ongoing work. I could present EPA's research agenda – the lines of work we are doing, what we have learned so far - and would be very interested in hearing the same from the FDA side. Please let me know if you would like me to contact someone on the FDA side to set this up.

62